×
Business

Gilead's Covid-19 Drug is Mediocre. It Will Be a Blockbuster Anyway.

Published Oct 29 2020 at 2:06 PM GMT
NY Times

NY Times / New York Times @nytimes.com

Continue reading at nytimes.com
Key
Points
  • Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.
Credit
Tags
Continue reading at nytimes.com
Trending

Stats

  • Published Oct 29, 2020 2:06 PM GMT